This is not a comment on the worth of the treatment, but it is a comment on the worthlessness of statistics in such small samples.
Heaven knows what there is for the statisticians to look at further, as we have been told they will. It's like getting a radiologist to look again (and again, and again) at a hopelessly fuzzy X-ray.
The lack of truly objective tests relating to improvement, such as cytological assays on brain cells, just compounds the statistical problem.
It is difficult to see where the company goes from here, given that it confronts established rules for testing in medical and drug assessments.
INHERENT PROBLEMS with pd trials using brain surgery, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.436M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $6.005K | 1.200M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2843571 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 3890236 | 6 |
View Market Depth
| Last trade - 15.14pm 21/07/2025 (20 minute delay) ? |
| 1AI (ASX) Chart |